Briacell Therapeutics Corp SEC Filings

BriaCell Therapeutics Corp. is conducting a best-efforts public offering of 10,775,000 Common Units at $1.25 each and up to 1,225,000 Pre-Funded Units at $1.249. Each Unit delivers one post-consolidation common share plus a five-year warrant exercisable at $1.50. The securities, as well as the 12.0 million warrants and 1.225 million pre-funded warrants issuable, will not be listed. ThinkEquity is placement agent and will receive a 7.5% cash fee ($0.09375/unit).

Assuming full subscription, gross proceeds equal $15.0 million; net proceeds are estimated at $13.4 million. Pro-forma cash would rise to roughly $25.9 million, while shareholders’ equity increases to $25.4 million (as of 30 Apr 2025). Funds are earmarked for working capital and advancement of BriaCell’s oncology pipeline, including the Fast-Track Phase 3 Bria-IMT study in metastatic breast cancer.

The transaction is highly dilutive: shares outstanding jump from 6.8 million to 18.8 million on conversion of the pre-funded warrants, before any warrant exercises. No minimum raise or escrow is required, so partial closings could leave the firm with less cash and investors without refund rights. Risk factors also cite recurring losses (YTD net loss $18.4 million), Nasdaq listing compliance history, and the absence of a trading market for the offered warrants.

Plum Acquisition Corp. III (Nasdaq: PLMJ) has filed a Form 25 with the U.S. Securities and Exchange Commission, signaling the removal of its Class A Ordinary Shares, Warrants and Units from listing and registration on the Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act of 1934.

• Issuer: Plum Acquisition Corp. III
• Exchange: Nasdaq Stock Market LLC
• SEC File No.: 333-253221
• Security classes affected: Class A Ordinary Shares, Warrants, Units
• Form signed: 10 Jul 2025 by Aravind Menon, Hearings Advisor, on behalf of Nasdaq
• Nasdaq certifies it has satisfied the requirements of Rule 12d2-2(b) for striking the securities from listing; the issuer has complied with Rule 12d2-2(c) for voluntary withdrawal.

The filing completes the procedural step required for delisting; once effective, the securities will no longer be quoted on Nasdaq and their registration under Section 12(b) will be terminated.

National Grid plc (NGG) released a Form 6-K detailing the voting outcome of its 2025 Annual General Meeting held on 9 July 2025. Shareholder participation was strong, with 76.48 % of issued share capital cast. All 26 resolutions—covering receipt of the Annual Report, declaration of the final dividend, re-election of the entire Board, auditor re-appointment, remuneration matters, political donations, increased borrowing limits, share-issuance authorities, share buy-backs and the ability to convene meetings on 14 days’ notice—were duly passed.

• The final-dividend resolution was approved with 99.85 % support (3.74 bn votes).
• All directors secured re-election; the lowest support was 94.74 % for Chair Paula Rosput Reynolds (196.7 m votes against).
• Special resolutions 23-26, which require 75 % approval in the UK, comfortably cleared the threshold (e.g., share buy-back authority at 99.74 %).
• Deloitte LLP was re-appointed auditor with 99.85 % support.

No new financial guidance or earnings data were disclosed; the filing is primarily procedural, confirming continued shareholder backing for management proposals and providing the company with flexibility on capital structure through approved authorities.

Blaize Holdings, Inc. (Nasdaq: BZAI) filed Prospectus Supplement No. 4 and an accompanying Current Report that together disclose a three-year, non-exclusive Sales Partner Referral Agreement executed on 30 June 2025 between wholly-owned subsidiary Blaize, Inc. and Burkhan LLC, an affiliate of Burkhan Capital.

Key commercial terms:

• Initial approved customer: BurTech Systems Tech LLC (BST), also affiliated with Burkhan.
• Potential purchase volume: BST will buy up to $56.5 million of Blaize products & services (GSP hardware, SDK, AI Studio, professional services) for resale to an unaffiliated end-user during Q2 2025-2026.
• Financing structure: BST fronts the purchase price; the end-user reimburses BST plus a 2.5 % financing fee.
• Commissions: Burkhan LLC earns up to 10 % of gross revenue on each qualifying purchase, paid 50 % cash / 50 % cash or Blaize common stock (VWAP-based), contingent on Blaize achieving a specified gross-margin threshold. Payments occur as Blaize receives cash.
• Termination: Either party may terminate for convenience with 30 days’ notice or for breach with 5 days’ notice.
• Governance: The Audit Committee approved the related-party transaction; confidentiality, non-circumvention and FCPA compliance clauses included.

Capital markets details:

• Up to 29.7 million new shares may become issuable upon warrant exercise under the underlying S-1.
• The referral agreement permits unregistered issuance of common stock to Burkhan LLC, relying on Section 4(a)(2) exemption, potentially dilutive but capped by Nasdaq Rule 5635(d).
• Closing prices on 7 July 2025: $2.83 per common share and $0.3534 per warrant.

Investment takeaways: If fully executed, the BST order would be material relative to Blaize’s historical scale, providing multi-year revenue visibility. However, purchase volumes remain up to $56.5 million and are subject to customer acceptance, contract margins, and early termination rights. Additionally, commissions (cash plus potential equity) reduce net profitability and may create dilution. The related-party nature warrants ongoing governance scrutiny.